# Thursdays Webinars EuroBloodNet: 

## Hereditary Stomatocytosis

Immacolata Andolfo, PhD
University of Naples, Federico II
CEINGE, advanced biothecnologies
ERN-EuroBloodNet subnetwork: Red blood cell defects
Naples - Italy

## Conflicts of interest

## I have nothing to disclose

## Learning objectives of the webinar



## Hereditary stomatocytosis (HSt)

> Wide spectrum of inherited hemolytic disorders in which the red cell membrane cation permeability is increased (cation leak)
$>$ The cation leak results in deregulation


Normal Erythrocyte


Stomatocyte of cellular volume, which leads to morphological abnormality of RBCs (stomatocytes, RBCs with a stoma across the center, at peripheral blood smear)
> The clinical presentation of HSt is highly variable: variable expressivity

$>$ Genetic and allelic heterogeneity


## Hereditary stomatocytosis (HSt): classification



## Syndromic

- Stomatin deficient cryohydrocytosis with mental retardation, seizures, hepatosplenomegaly (GLUT1)
- Phytosterolemia non-leaky stomatocytosis with macrothrombocytopenia (ABCG5; ABCG8)
- Dehydrated Hereditary Stomatocytosis (DHS1) with perinatal edema and/or pseudohyperkalemia (PIEZO1)


## Reference

 Network complex diseases
## Syndromic HSt: Stomatin deficient cryohydrocytosis




European Reference Network
for rare or low prevalence complex diseases

Diseases (ERN EuroBloodNet)
$\checkmark$ It is a rare form of stomatocytosis associated with a cold-induced cation leak, hemolytic anemia, hepatosplenomegaly, cataracts, seizures, mental retardation, and movement disorder.
$\checkmark$ It is caused by mutations in SLC2A1 gene, that codifies for the GLUT1 transporter (associated with both loss of glucose transport and a cation leak). Autosomal recessive inheritance.
$\checkmark$ It is characterized by lipid metabolic disorder, stomatocytic hemolysis, and macrothrombocytopenia.
$\checkmark$ They showed normal erythrocyte cation content.

$\checkmark$ The causative genes are: ABCG5 and ABCG8, that codify for two ATP-cassette transporters that mediate efflux of dietary sterols from the small intestine. Autosomal recessive inheritance (ABCG5/ABCG5; ABCG8/ABCG8; ABCG5/ABCG8).
$\checkmark$ Incorporation of sterols into RBCs and platelets results in abnormal morphology and function.


| $l$ |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
| Table 2. Serum Sterols Levels of Phytosterolemia Patients in 3 Families |  |  |  |  |  |

## Hereditary stomatocytosis (HSt): classification



## Non-Syndromic HSt: Overhydrated Hereditary Stomatocytosis


$\checkmark$ OHS is characterized by anemia of a variable degree with macrocytosis, low MCHC, and a right shift of the osmolarity curve at ektacytometric analysis
$\checkmark$ It is characterized by an increase in the monovalent cation leak also associated with the absence of stomatin
$\checkmark$ It is caused by mutations in the ammonium transporter RHAG (autosomal dominant inheritance)
$\checkmark$ At peripheral blood smear we can observe more than 20\% of stomatocytes


Thursdays Webinars

## Non-Syndromic HSt: Cryohydrocytosis


$\checkmark$ Cryohydrocytosis is characterized by increased permeability to $\mathrm{Na}+/ \mathrm{K}+$ cations at low temperatures $\left(0-4^{\circ} \mathrm{C}\right)$.
$\checkmark$ It is a mild hemolytic anemia due to a minimal cation leak.
$\checkmark$ Its pathophysiology has been linked to missense mutations in the SLC4A1 gene that encodes the band 3 protein.
$\checkmark$ These substitutions convert band 3 from an anion exchanger into a cation $-2-2$ channel, which is a pathogenic mechanism entirely different from the loss-offunction mechanism that causes hereditary spherocytosis.

## Non-Syndromic HSt: Familial Pseudohyperkalemia


$\checkmark$ Dominantly inherited genetic trait
$\checkmark$ Characterized by a temperature-dependent, in vitro, loss of $\mathrm{K}^{+}$cation from red cells
$\checkmark$ Plasma $[K+]$ was increased when measured in blood stored at or below body temperature
$\checkmark$ The patients show alterations in MCV
$\checkmark$ Missense mutations in ABCB6 gene were identified in FP
European
Reference
Network
for rare or low prevalence complex diseases

|  |  | ABCB6 patients FP |
| :---: | :---: | :---: |
| Number of patients (\%) |  | 11 (15.1) |
| Gender (female/male) |  | $\begin{gathered} 10(90.9) / 1 \\ (9.1) \end{gathered}$ |
| Onset of symptoms (years) |  | $\begin{array}{r} 42.5 \pm 6.6 \\ (40.5 ; 8) \end{array}$ |
| Age of diagnosis (years) |  | $\begin{array}{r} 47.1 \pm 5.6 \\ (43.5 ; 8) \end{array}$ |
| Blood count |  |  |
|  | Refrange ${ }^{\text {c }}$ |  |
| $\mathrm{RBC}\left(10^{6} / \mu \mathrm{L}\right)$ | 3.9-5.6 | $\begin{aligned} & 3.6 \pm 0.4(3.8 ; \\ & \text { 11) } \end{aligned}$ |
| $\mathrm{Hb}(\mathrm{g} / \mathrm{dL})$ | 11.0-16.0 | $\begin{gathered} 13.5 \pm 0.4 \\ \quad(13.1 ; 11) \end{gathered}$ |
| Hct (\%) | $33.0-45.0$ | $\begin{gathered} 42.6 \pm 1.3 \\ \quad(42.0 ; 11) \\ \hline \end{gathered}$ |
| MCV (fL) | 70.0-91.0 | $\begin{gathered} 101.3 \pm 2.3 \\ (100.2 ; 11) \end{gathered}$ |
| $\mathrm{MCH}(\mathrm{pg})$ | 23.0-33.0 | $\begin{gathered} 31.1 \pm 0.6 \\ (31.4 ; 11) \end{gathered}$ |
| MCHC (g/dL) | 23.0-33.0 | $\begin{gathered} 33.2 \pm 0.9 \\ (32.5 ; 11) \end{gathered}$ |
| Retics count (v103/u) | - | $\begin{array}{r} 140.3 \pm 35.7 \\ \hline \end{array}$ |
| Retics \% | 0.5-2.0 | $\begin{aligned} & 2.9 \pm 1.2(2.9 ; \\ & \text { 2) } \end{aligned}$ |

Thursdays Webinars

## ABCB6 variants screening in blood donors population

$\checkmark$ Variants in ABCB6 gene are present in healthy subjects and in blood donor population
$\checkmark$ Storage of FP blood causes a significant increase in blood K+ levels causing problems mostly in pediatric/neonatal care, indeed several cases of whole blood transfusion in infants leading to cardiac arrest and death have been described
$\checkmark$ Genetic test for FP could
be used to screen
potential donors of blood



Blood samples

## Syndromic/Non-Syndromic HSt: Dehydrated Hereditary Stomatocytosis



## Dehydrated Hereditary Stomatocytosis (DHS)

| Main characteristics | $\mathrm{Hb} \downarrow \mathrm{MCV} \uparrow \mathrm{MCHC} \uparrow$ |
| :--- | :--- |
| Macrocytic anemia | Ret count $\uparrow \mathrm{LDH} \uparrow \mathrm{Hap} \downarrow \mathrm{Bil}$ (tot, ind) $\uparrow$ <br> Hemolysis <br> increased risk of severe thromboembolic <br> complications |
| Splenomegaly and gallstones | $<20 \%$ | | Variable numbers of stomatocytes at PB |
| :--- |
| smear |

## PIEZO1: physiological functions

$\checkmark$ PIEZO1 is a mechanoreceptor (non-selective cation channel activated by several mechanical stimuli) that forms a trimeric propeller-like structure of about 900 kDa in the plasma membrane
$\checkmark$ It plays an important physiological role in several biological processes such as regulation of urinary osmolarity, control of blood pressure, regulation of hydration and volume of erythrocytes, sensor of epithelial cell crowding and stretching, formation and development of blood and lymphatic vessels
$\checkmark$ It is present only at a few hundred copies per RBC but functions as major determinant of the RBC hydration status


European
Reference
Network
for rare or low prevalence complex diseases

* Network

Hematological
Diseases (ERN EuroBloodNet)


## Gain-of-function (GOF) mutations in PIEZO1

$\checkmark$ Several electrophysiology studies demonstrated that the pathogenic variants cause a gain-offunction phenotype with delayed inactivation of the channel
$\checkmark$ RBCs dehydration is due to an excessive potassium efflux and calcium influx, accompanied by further potassium efflux through the Gardos channel and osmotic efflux of water
$\checkmark$ Other mechanisms of PIEZO1 dysfunction include altered response to osmotic stress and membrane trafficking (phenotype heterogeneity of the disease)



## KCNN4: second causative gene of DHS

> KCNN4 gene encodes for the Gardos channel (KCa3.1), the erythroid $\mathrm{Ca}^{2+}$-sensitive $\mathrm{K}^{+}$channel
> The families described until now are few (recurrent mutations R356H, V282M and V282R)
$>$ The mutated channel showed a higher activity when compared to the wild type channel demonstrating that the mutations are gain-of-function

> Is it the same disease? "Gardos channelopathy". There are differences in cellular pathophysiology and clinical presentation



Reference
Reference
Network
for rare or low prevalence complex diseases

Rapetti Mauss et al, Blood 2015; Andolfo et al, AJH 2015,
$\%$ Network
Hematological
Diseases (ERN EuroBloodNet)

## DHS phenotypes: PIEZO1 vs "Gardos channelopathy"

DHS1 - PIEZO1
DHS2 - KCNN4- Gardos

## Two large cohort studies: 123 and 126 patients with HSt



| Patients with PIEZO1 mutations | High-rank $(n=14)$ | Low-rank $(n=15)$ | P ${ }^{\text {8 }}$ |
| :---: | :---: | :---: | :---: |
| Age at diagnosis (years) | $17.4 \pm 3.3$ (17.5; 14) | $24.9 \pm 6.5$ (20.0; 11) | 0.39 |
| Gender (Female/Male) | $4(28.6) / 10$ (71.4) | 9 (60.0)/6 (40.0) | 0.09 |
| Hematological data |  |  |  |
| Hb (g/dL) | $11.4 \pm 0.8(11.3 ; 14)$ | $12.6 \pm 0.4$ (12.2; 15) | 0.30 |
| MCH (pg) | $35.0 \pm 1.5(36.0 ; 13)$ | $36.5 \pm 1.5$ (36.0; 15) | 0.84 |
| MCHC (g/dL) | $36.7 \pm 1.7$ (34.8; 14) | $33.9 \pm 0.3$ (33.7; 15) | 0.12 |
| Retics abs count ( $\times 10^{3} / \mathrm{LL}$ ) | $181.3 \pm 34.4$ (165.6; 13) | $153.5 \pm 26.4(139.3 ; 13)$ | 0.57 |
| Laboratory data, iron balance, and transfusion regimen |  |  |  |
| Total bilirubin (mg/dL) | $4.4 \pm 0.7$ (4.3; 14) | $2.5 \pm 0.7(1.5 ; 8)$ | 0.06 |
| LDH (U/L) | $333.8 \pm 51.0$ (315.0; 11) | $232.6 \pm 18.2$ (242.5; 8) | 0.17 |
| Ferritin ( $\mathrm{ng} / \mathrm{mL}$ ) | $\begin{aligned} & 720.9 \pm 129.3(626.0 \text {; } \\ & 14) \end{aligned}$ | $196.7 \pm 57.1$ (182.5; 6) | 0.02 |
| Ferritin level/dosage age ${ }^{\ddagger}$ | $47.2 \pm 8.3$ (38.4; 14) | $17.4 \pm 3.7(16.3 ; 6)$ | 0.01 |




Andolfo et al, AJH 2018; Picard et al., Haem. 2019


Thursdays Webinars

## Learning objectives of the webinar



Diagnosis and therapy of HSt

## Diagnostic workflow of HSt



## Genetic testing of HSt in the NGS era


$\checkmark 18 \%$ of patients with clinical suspicion of congenital dyserythropoietic anemias (CDAs), mainly CDAI and II, carried mutations in PIEZO1 gene.

## Differential diagnosis

$>$ DHS is often misdiagnosed, at clinical level, as hereditary spherocytosis (HS) or congenital dyserythropoietic anemias (CDAI/II)
> In several cases DHS can also be misdiagnosed as hereditary hemochromatosis
> The genetic analysis is crucial also to avoid not useful treatments as for example splenectomy
> It is important to evaluate the possible co-inheritance of

## MCV $\uparrow$ <br> Ferritin $\uparrow$ <br> DHS <br> LDH $\uparrow$ Hapt $\downarrow$ <br> Bil ind $\uparrow$ <br> Splenomegaly <br> $\mathrm{MCV}=$ <br> Ferritin $=$ <br> HS

Right shift ekta.
DiMax other genetic traits that could account for variability of the phenotype observed


Hypercellular bone marrow with erythroid hyperplasia (mimicking myelodysplastic syndrome) in a patient with DHS Paessler M, Hartung H. Blood. 2015


Thursdays Webinars

## Standard treatment and possible future therapy

$\checkmark$ The first-line treatment is based only on supportive care: folates, Vit.B12, transfusions, iron chelation.
$\checkmark$ Splenectomy is contraindicated (increased risk of thrombosis).
$\checkmark$ SENICAPOC (ICA -17043) is a Gardos channel antagonist, previously




Thursdays Webinars

## Learning objectives of the webinar



Dehydrated hereditary stomatocytosis: role of PIEZO1 in RBCs

## Piezo1 Gain-of-Function Mice

Constitutive Piezo1 GOF and blood-cell-specific Piezlo1 GOF transgenic mice (R2456H) showed:
$\checkmark$ Stomatocytes at PB, reduced osmotic fragility, and splenomegaly
$\checkmark$ Mild anemia, with lower Hb level and increased ret. Number/MCV

Gain-of-function Piezo1 mice display hallmark clinical features observed in human DHS patients, including RBC dehydration, mild anemia,

Piezo1 GOF
 RBC


European
Reference Network for rare or low pre
complex diseases

## Piezo1 GOF mutations attenuate Plasmodium infection


$\checkmark$ GOF PIEZO1 mice showed increased survival rate after infection and decreased parasitemia.
$\checkmark$ A novel human GOF PIEZO1 allele, E756del, is present in a third of the African population.
$\checkmark$ RBCs from individuals carrying this allele are dehydrated and resistant to malaria.

## PIEZO1 activation delays erythroid differentiation and reticulocyte

 maturation in DHS1

European
Reference
Network
for rare or low prevalence
complex diseases
\% Network
Hematological
Diseases (ERN EuroBloodNet)

## Learning objectives of the webinar



## Hepatic iron overload in DHS1

$\checkmark$ Severe iron overload with several cases of hepatosiderosis has been described for PIEZO1 patients.
$\checkmark$ Hepatic iron overload is independent from the degree of anemia, the transfusion regimen, and the splenectomy
$\checkmark$ Ferritin and ferritin/age ratio is very high in DHS1. There is a poor correlation between ferritin levels and liver iron content.
$\checkmark$ Most of the patients with a severe phenotype (mostly with impaired iron balance) carried mutations in the pore domain, while most of the
 patients with mild phenotype exhibited variations in the non-pore domain


B


|  | PIEZO1 <br> patients <br> DHS1 | KCNN4 <br> patients <br> DHS2 |
| :--- | :--- | :--- |
| Number of patients (\%) | $36(49.3)$ | $5(6.8)$ |

## Hepcidin and ERFE dosage in DHS1 patients

(A)
(C)

(B)

(D)

$\checkmark$ Hepcidin resulted highly reduced in DHS1 patients compared to HC and CDAll patients.
$\checkmark$ ERFE showed a slight, but not significant, increased levels in DHS1 compared to HC.


## PIEZO1 in liver: physiological role






$\checkmark$ Intracellular calcium concentration increases after PIEZO1 activation by Yoda-1 in primary hepatocytes
$\checkmark$ Activation of PIEZO1 by both Yoda-1 and GoF mutations cause Hamp suppression in hepatic cells

## Impaired BMP-SMADs pathway in PIEZO1-GOF mutants


$\checkmark$ HAMP gene expression is regulated by the BMP/SMADs pathway
$\checkmark$ PIEZO1 activations leads to ERK1/2 phosphorylation in other cells


[^0] PIEZO1 was activated by Yoda-1 (1.5 1 M)

* Network

Diseases (ERN EuroBloodNet)

$\checkmark$ PIEZO1 GOF mutants showed increased phosphorylation of ERK1/2 in hepatic cells and inhibition of BMP-SMADs pathway
$\checkmark$ The inhibition of BMP/SMADs signaling was
The inhibition of BMP/SMADs signaling was
confirmed by the downregulation of the target genes: SMAD6/SMAD7/ID1/ID3

$\checkmark$ The inhibition of PIEZO1 by GsMTx-4 rescued the Hamp and ID1 gene expression.


## Model of pathogenic mechanism of DHS



European
Reference
Network
for rare or low prevalence
complex diseases

## Proposed model: PIEZO1 regulation of hepatic iron metabolism

Hepatic cell



## Take home messages

$\checkmark \quad$ HSt are a wide spectrum of inherited hemolytic disorders in which the RBC membrane cation permeability is increased.
$\checkmark$ DHS is the most frequent condition within this class of anemias. It is an autosomal dominant hemolytic anemia caused by GOF mutations in both PIEZO1 and KCNN4 genes.
$\checkmark$ The diagnosis of Hst is very challenging because of the presence of overlapping phenotypes, variable expressivity, allelic and genetic heterogeneity. DHS is in differential diagnosis with HS and CDAs.
$\checkmark$ GOF mutations in PIEZO1 caused impaired erythroid differentiation and reticulocytes maturation.
$\checkmark$ GOF mutations in PIEZO1 cause decreased Plasmodium infection.
$\checkmark$ Iron overload in DHS1 is directly caused by GOF mutations of PIEZO1 at hepatic level by impairing of Hamp gene expression.

## Acknowledgments

UOC Medical Genetics and Hereditary Anemias Research Lab University of Naples "Federico II" Ceinge, advanced biotechnologies

Prof. Achille Iolascon Roberta Russo

Barbara Eleni Rosato Roberta Marra Francesco Manna Simone Della Monica


[^0]:    Camaschella C. et al., Haematologica 2020

